Pharmaceutical - Clinigen Group

Filter

Current filters:

Clinigen Group

Popular Filters

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

20-08-2014

UK-based Clinigen Group has acquired the global rights to the oncology support therapy Ethyol (amifostine)…

ClinigenClinigen GroupEthyolLicensingOncologyPharmaceuticalTreatment for head and neck cancerUK

Clinigen backs white paper calling for recognition of early access schemes

Clinigen backs white paper calling for recognition of early access schemes

08-08-2014

UK-based Clinigen Group has published a new International Society for Pharmaceutical Engineering (ISPE)…

Clinigen GroupHealthcarePharmaceuticalRegulationUKUnited States

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Clinigen to provide first access to anti-bacterial Vibativ in Europe

Clinigen to provide first access to anti-bacterial Vibativ in Europe

08-01-2014

UK-based Clinigen Group has announced the initiation of an early access program to provide the anti-bacterial…

Antibiotics and Infectious diseasesClinigen GroupEuropeLicensingPharmaceuticalProductionUKVibativ

Interview: Clinigen’s CEO Peter George on the company’s record growth

Interview: Clinigen’s CEO Peter George on the company’s record growth

15-11-2013

If there is one pharma company bucking the trend of shaky financial results it is the Clinigen Group.

BoardroomClinigen GroupFoscavirInterviewsOncologyPharmaceuticalRare diseasesUK

Clinigen acquires oncology support therapy Cardioxane from Novartis

26-03-2013

UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

Back to top